文献速递病毒性肝炎艾滋病与性传播感染

治疗即预防试验:瑞士HIV队列中男男性行为者丙型肝炎消除

A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

在瑞士HIV队列研究的HIV感染男男性行为者中开展全国性HCV微消除项目,分三阶段系统筛查与直接抗病毒药物治疗。筛查3715人发现177例现症感染,150人治疗,149人治愈;再筛查发现13例新发感染。

要点

  • 系统筛查联合DAA治疗在HIV感染MSM中可行,治愈率达93%。
  • 该模式可为其他国家实现WHO HCV消除目标提供参考。

核心结论

  • 在HIV感染MSM中开展系统性的基于人群的HCV微消除项目可行,并导致HCV发病率和患病率显著下降。

研究设计与样本

  • 全国性HCV微消除项目,纳入瑞士HIV队列研究中HIV感染的男男性行为者,分三阶段:筛查、治疗、再筛查。
  • 阶段A(2015年10月-2016年6月)系统筛查HCV-RNA;阶段B(2016年6月-2017年2月)对现症感染者提供DAA治疗;阶段C(2017年3月-2017年11月)再筛查并治疗新发感染。

主要发现

  • 筛查3715/4640(80%)MSM,发现177例(4.8%)现症HCV感染,其中150例(85%)开始DAA治疗,149例(99.3%)治愈。
  • 对2930/3538(83%)既往HCV-RNA阴性MSM再筛查,发现13例(0.4%)新发HCV感染。

临床怎么用

  • 对HIV感染MSM人群实施系统HCV筛查和DAA治疗可有效降低HCV传播。
  • 该微消除模式可推广至其他追求WHO HCV消除目标的地区。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2016, the World Health Organization (WHO) introduced global targets for the elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide HCV micro-elimination program among men who have sex with men (MSM) living with human immunodeficiency virus (HIV) from the Swiss HIV Cohort Study (SHCS) to test whether the WHO goals are achievable in this population. METHODS: During phase A (10/2015-06/2016), we performed a population-based and systematic screening for HCV-RNA among MSM from the SHCS. During phase B (06/2016-02/2017) we offered treatment with HCV direct-acting antiviral (DAA) agents to MSM identified with a replicating HCV infection. During phase C (03/2017-11/2017), we offered rescreening to all MSM for HCV-RNA and initiated DAA treatment in MSM with replicating infections. RESULTS: We screened 3715/4640 (80%) MSM and identified 177 with replicating HCV infections (4.8%); 150 (85%) of whom started DAA treatment and 149 (99.3%) were cured. We rescreened 2930/3538 (83%) MSM with a prior negative HCV-RNA and identified 13 (0.4%) with a new HCV infection. At the end of the micro-elimination program, 176/190 MSM (93%) were cured, and the HCV incidence rate declined from .53 per 100 patient-years (95% CI, .35-.83) prior to the intervention to .12 (95% CI, .03-.49) by the end of 2019. CONCLUSIONS: A systematic, population-based HCV micro-elimination program among MSM living with HIV was feasible and resulted in a strong decline in HCV incidence and prevalence. Our study can serve as a model for other countries aiming to achieve the WHO HCV elimination targets. CLINICAL TRIALS REGISTRATION: NCT02785666.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Braun DL, Hampel B, Ledergerber B, et al. A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clin Infect Dis. 2021. PMID: 32761122. doi:10.1093/cid/ciaa1124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。